Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

02.08.2017 | short review | Ausgabe 4/2017

memo - Magazine of European Medical Oncology 4/2017

ASCO update – what is new in the systemic treatment of advanced soft tissue sarcomas?

memo - Magazine of European Medical Oncology > Ausgabe 4/2017
MD Joanna Szkandera


Soft tissue sarcomas (STS) are a rare and heterogeneous group of malignant tumors that substantially differ in the underlying biology, natural course and treatment response. In locally advanced or metastatic disease, systemic treatment represents the main therapeutic approach. Anthracycline-based chemotherapy and its combination with ifosfamide has been used as the gold standard in the first-line treatment of advanced disease for decades; however, as increasing evidence favors the use of histology-tailored therapy, novel cytotoxic agents and targeted therapies are currently under intense investigation. Additionally, immunotherapeutic agents have been explored in several STS studies, showing promising results in specific histological subtypes. This article provides a brief overview of the standard systemic treatment options in advanced STS and a summary of the highlights of the STS trials presented at the American Society of Clinical Oncology (ASCO) annual meeting 2017.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2017

memo - Magazine of European Medical Oncology 4/2017 Zur Ausgabe